Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Rhea-AI Summary
Daxor (Nasdaq: DXR) announced April 8, 2026 the launch of a new BVA program at a high-volume cardiology center in Southwest Ohio. The program uses Daxor’s Tennessee-based ezBVA Lab workflow to deliver 24-hour turnaround on blood volume analysis without onsite lab infrastructure.
This lab-as-a-service integration aims to enable data-driven heart failure care, leverage existing reimbursement codes, reduce capital barriers for providers, and speed clinical adoption across the region.
Positive
- None.
Negative
- None.
News Market Reaction – DXR
On the day this news was published, DXR gained 2.31%, reflecting a moderate positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $55.13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DXR was down 1.66% pre-news with no momentum scanner flags. Peers were mixed: AKYA -8.51%, MLSS -4.05%, ZJYL -1.95%, ZTEK -2.5%, while PDEX rose 1.57%, pointing to stock-specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Clinical data update | Positive | -2.9% | New SCCM 2026 data validating BVA’s accuracy versus capillary leak indices. |
| Mar 17 | Product showcase | Positive | +0.2% | ACC.26 exhibit of next-gen portable BVA highlighting reduced readmissions and mortality. |
| Mar 10 | Product launch | Positive | +1.6% | Debut of rapid portable blood volume analyzer at SCCM 2026 critical care congress. |
| Mar 09 | Investor conference | Neutral | -0.7% | CEO participation and presentation at iAccess Virtual Alpha Best Ideas conference. |
| Mar 03 | Corporate update | Positive | -0.9% | Shareholder letter on 2025 transformation, revenue growth, and January 2026 offering. |
Recent positive clinical, product, and corporate updates have often seen muted or even negative next-day price moves, indicating a history of mixed short-term reactions to favorable news.
Over the last several weeks, Daxor reported multiple milestones, including 510(k) clearance in August 2025, unaudited operating revenue up 45% year-over-year, and new portable Blood Volume Analyzer launches highlighted at SCCM and ACC conferences. Clinical data from SCCM 2026 emphasized BVA’s specificity in detecting capillary leak. Despite this, 24-hour moves around these events ranged from about -2.9% to +1.63%, showing that strong fundamental or clinical updates have not always translated into consistent upside in the immediate aftermath.
Market Pulse Summary
This announcement highlights further commercialization of Daxor’s blood volume analysis platform, extending ezBVA Lab’s 24-hour turnaround service into a high-volume Ohio cardiology center. It builds on prior developments such as 510(k) clearance for the next‑generation portable analyzer and 45% 2025 revenue growth. Investors may track additional hospital adoptions, follow-on clinical outcomes data, and any future capital-raising steps from existing registration statements to assess how effectively this "lab-as-a-service" strategy converts into scalable revenue and margin improvement.
Key Terms
lab-as-a-service technical
reimbursement codes financial
volume status medical
AI-generated analysis. Not financial advice.
Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor’s state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management.
By leveraging Daxor’s proprietary, Tennessee-based ezBVA Lab workflow, the facility gains access to 24-hour turnaround on gold-standard blood volume metrics without the need for onsite laboratory infrastructure. This "lab-as-a-service" model allows for rapid, data-driven clinical decision-making across the region’s cardiology patient population.
“We are enabling clinicians to move the standard of care from proxy markers and subjective assessment of volume status to data-driven precision,” said Michael Feldschuh, Daxor CEO and President. “By removing the capital investment hurdle through our ezBVA Lab service and utilizing existing reimbursement codes, we are clearing the path for more rapid clinical adoption. This model not only improves patient outcomes but also contributes to reducing systemic healthcare costs.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
